Moderna Completes Enrollment of Phase 3 COVE Study of mRNA Vaccine Against COVID-19 (mRNA-1273)

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 22, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it has completed enrollment

Welcome move in fight against suicide

One of the nation’s greatest modern tragedies is its rising suicide rate, especially among young people. It remains the single biggest cause of death among Australians aged 15 to 44 years, and the emotional trauma